



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information

Description:	BAFF/APRIL Dual Antagonist is a fusion protein composed of TACI (transmembrane activator and CAML interactor), and the Fc domain of human IgG1. This protein was affinity purified.
Background:	BAFF (TNF family ligand B-cell Activating Factor), also known as BLyS, TALL-1 or CD257, is encoded by the TNFSF13B gene and is a Type II membrane-bound protein, which can be released as a soluble ligand upon proteolytic processing. This cytokine is a ligand for the receptors Transmembrane Activator and CAML Interactor (TACI or TNFRSF13B), BAFF Receptor (BAFFR, or TNFRSF13C) and B-cell Maturation Antigen (BCMA, TNFRSF17). These interactions promote cell survival and play a crucial role in B cell development. APRIL (A proliferation-inducing ligand), also known as TNSF13 or CD256, activates a signaling pathway that participates in the regulation of B-cell development, autoimmunity, and long-term plasma cell survival. APRIL expression is significantly elevated in multiple myeloma (MM), and it has been demonstrated that activation of BCMA by APRIL promotes tumor growth, chemoresistance, and immunosuppression in the bone marrow microenvironment. Anti-APRIL monoclonal antibodies have recently progressed to clinical trials for MM. The development of a modified TACI (transmembrane activator and CAML interactor) domain resulted in Povetacept, or ALPN-303, a dual inhibitor of APRIL and BAFF, with potential applications in the treatment of autoimmune disorders.
Species:	Human
Concentration:	1.72 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	31 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	Assay was done according to BCMA:APRIL[Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79722) using various amounts of BAFF/APRIL Dual Antagonist.
Applications:	Useful for blocking assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



BAFF/APRIL Dual Antagonist Blocking Activity

